Modulating Innate Immune Responses to Curli Fibers Through Protein Engineering

This study demonstrates that engineering *E. coli* Nissle 1917 to produce curli fibers fused with a TLR2 antagonist (SSL3) effectively transforms these naturally inflammatory amyloids into programmable immune modulators that robustly suppress innate immune activation in human cells, establishing a design principle for tuning host-microbe interactions at mucosal surfaces.

The Gist

The Big Picture: Taming the "Alarm Bell"

Imagine your body's immune system is a high-tech security team patrolling your gut (your digestive tract). Their job is to spot intruders (bad bacteria) and sound the alarm. One of their most important alarm bells is called TLR2.

Usually, this alarm is helpful. It wakes up the immune system to fight infections. However, sometimes the alarm gets stuck in the "ON" position. When this happens, it causes chronic inflammation, leading to painful diseases like Crohn's disease, lupus, or even issues in the brain like Parkinson's.

One of the things that triggers this alarm is a tiny, sticky protein fiber called Curli. Think of Curli as a "Velcro strip" that bad bacteria (and even some good ones) use to stick to your gut lining. Unfortunately, your immune system mistakes this Velcro for a weapon and starts screaming, "INTRUDER!" even when there isn't one.

The Problem: Good Bacteria with Bad Hair

The scientists in this study used a famous "good guy" bacterium called E. coli Nissle 1917. This bacterium is already used as a probiotic (a healthy supplement) to help people with gut issues. But, this good bacterium naturally grows Curli fibers.

The Dilemma: We want to use this good bacterium to deliver medicine to the gut, but its natural "hair" (Curli fibers) keeps accidentally setting off the immune alarm, causing the very inflammation we are trying to cure.

The Solution: Engineering a "Silent" Bacterium

The team asked: Can we genetically tweak this good bacterium so it still grows Curli fibers, but those fibers act like a "mute button" for the immune alarm instead of a trigger?

They tried two different strategies to modify the Curli fibers:

Strategy 1: The "Bubble Wrap" Approach (Steric Shielding)

• The Idea: Imagine the Curli fiber is a microphone that triggers the alarm. The scientists tried wrapping the microphone in thick, fluffy "bubble wrap" (a protein called SELP). The hope was that the bubble wrap would physically block the immune system from touching the microphone.
• The Result: It worked a little bit. It muffled the sound, but not enough. The immune system could still hear the alarm ringing, especially when there was a lot of noise (other triggers) around. It was like trying to stop a fire alarm by putting a sock over it; it gets quieter, but it still goes off.

Strategy 2: The "Fake Key" Approach (Direct Antagonism)

• The Idea: Instead of just covering the microphone, the scientists attached a "fake key" to the fiber. This key is a protein called SSL3. The SSL3 protein is a known "spoiler" that fits perfectly into the immune alarm's lock (the TLR2 receptor) but doesn't turn it on. It jams the lock.
• The Result: This was a huge success. The Curli fibers, now wearing the SSL3 "fake key," didn't just muffle the alarm; they completely jammed the system. Even when the scientists added other real triggers to the mix, the SSL3-fibers held the lock shut, preventing the immune system from screaming.

The Experiment: Testing the New Bacteria

The team tested these engineered bacteria in three ways:

1. The Robot Test (Reporter Cells): They used computer-controlled cells that light up when the immune alarm goes off. The "Bubble Wrap" bacteria made the lights dim a little, but the "Fake Key" bacteria kept the lights completely off.
2. The Chaos Test (Competitive Inhibition): They added the bacteria to a mix of other strong immune triggers. The "Fake Key" bacteria were like a superhero shield, blocking the triggers from hitting the alarm, even when the triggers were strong. The "Bubble Wrap" bacteria got overwhelmed.
3. The Real World Test (Human Cells): This is the most important part. They used real human immune cells grown in a lab.
   • The normal bacteria made the human cells angry and release inflammatory chemicals (like IL-8).
   • The "Bubble Wrap" bacteria did almost nothing to stop the anger.
   • The "Fake Key" bacteria successfully calmed the human cells down, stopping them from releasing inflammatory chemicals.

Why This Matters

This study is like finding a way to turn a "Do Not Disturb" sign into a functional part of a security system.

• Before: If you wanted to use bacteria to treat gut disease, you had to worry about them accidentally causing inflammation.
• Now: We have a blueprint for "programming" bacteria to actively calm the immune system. By attaching a specific "jamming" protein to the bacteria's natural fibers, we can create a living drug that sits in the gut and constantly tells the immune system, "Everything is fine, stand down."

The Takeaway

The scientists proved that you can take a natural bacterial structure that causes inflammation and, through genetic engineering, turn it into a tool that stops inflammation.

While the "bubble wrap" idea was a good try, the "fake key" (SSL3) was the winner. This opens the door for a new generation of programmable probiotics—living medicines that can be designed to specifically turn off the immune alarms in diseases like Crohn's, lupus, or even neurodegenerative diseases, right where the problem starts: in the gut.

Technical Summary

1. Problem Statement

• Context: Curli fibers are functional amyloids produced by Escherichia coli and other Enterobacteriaceae. While they are essential for biofilm formation and host colonization, they are potent activators of Toll-like receptor 2 (TLR2), a key pattern recognition receptor in the innate immune system.
• The Challenge:
  • Therapeutic Limitation: The intrinsic immunostimulatory nature of curli fibers limits their utility as programmable scaffolds for engineered probiotic systems, as they inadvertently trigger inflammation.
  • Pathological Relevance: Dysregulated TLR2 activation is linked to chronic inflammatory diseases, including Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), neurodegenerative disorders (e.g., Parkinson's), and sepsis. Curli fibers have been directly implicated in driving autoantibody production in lupus and cross-seeding $\alpha$-synuclein in Parkinson's.
  • Current Gap: Existing therapies rely on systemic immunosuppression, which lacks specificity and carries off-target risks. There is a need for localized, receptor-specific modulation of TLR2 at mucosal surfaces without compromising the structural benefits of microbial amyloids.

2. Methodology

The researchers utilized synthetic biology to engineer the probiotic strain E. coli Nissle 1917 (EcN) to produce modified curli fibers capable of inhibiting TLR2.

• Genetic Engineering Strategy:
  • Host Strain: Endogenous curli operons (csgBACEFG) were deleted from the EcN chromosome to eliminate background fiber production.
  • Expression System: A synthetic curli operon was introduced on a temperature-inducible plasmid (ePM1) derived from the native pMUT1 plasmid. This allowed controlled expression of engineered CsgA variants.
  • Design Variants: Two mechanistically distinct fusion strategies were tested by appending C-terminal domains to the CsgA protein:
    1. Steric Shielding: Fusion of Silk-Elastin-Like Protein (SELP) sequences (specifically S6E11) to physically occlude TLR2-binding sites.
    2. Direct Antagonism: Fusion of Staphylococcal Superantigen-Like protein 3 (SSL3), a known TLR2 antagonist, to directly block the receptor binding site.
• Characterization & Purification:
  • Fibers were produced in E. coli and purified using denaturing conditions (8 M guanidine hydrochloride) followed by refolding.
  • To avoid confounding endotoxin (LPS) signals, proteins were expressed in ClearColi™ (an endotoxin-free strain) rather than standard BL21.
  • Structural integrity was verified via Congo red binding, Western blot, Transmission Electron Microscopy (TEM), and Circular Dichroism (CD) spectroscopy.
• Assays:
  • Reporter Assays: HEK-Blue™ hTLR2 cells were used to quantify NF-$\kappa$B activation.
  • Competition Assays: Engineered fibers were pre-incubated with cells before stimulation with diverse TLR2 agonists (CU-T12-9, heat-killed S. typhimurium, Lipoteichoic Acid).
  • Primary Cell Models: Human monocyte-derived dendritic cells (MoDCs) were stimulated with purified fibers to measure cytokine secretion (IL-8, IL-6, IL-1$\beta$) and gene expression via RT-qPCR.

3. Key Contributions

• Proof of Concept: Demonstrated that the CsgA amyloid scaffold can be genetically reprogrammed to switch from an immune activator to an immune inhibitor without disrupting fiber assembly.
• Mechanistic Insight: Established that direct receptor antagonism (via SSL3) is superior to steric shielding (via SELP) for effective immune modulation in complex primary cell environments.
• Platform Development: Created a modular, programmable interface for engineering host-microbe interactions, specifically targeting mucosal immunity.

4. Key Results

• Structural Integrity: All engineered variants (WT, CsgA-S6E11, CsgA-SSL3) successfully assembled into structurally intact amyloid fibers with morphology comparable to wild-type curli, as confirmed by TEM and Congo red assays.
• Reduced Intrinsic Activation:
  • In HEK-TLR2 reporter cells, both engineered variants showed significantly reduced intrinsic NF-$\kappa$B activation compared to wild-type curli.
  • CsgA-SSL3 reduced activation to ~0.19-fold relative to the positive control, while CsgA-S6E11 reduced it to ~0.19-fold (at high density) but showed dose-dependent variability.
• Competitive Inhibition (Agonist Challenge):
  • SSL3 Fusion: Achieved near-complete inhibition (>98%) of TLR2 activation induced by diverse agonists (synthetic, pathogen-derived, and cell wall components). Crucially, this inhibition remained robust even as agonist concentration increased.
  • SELP Fusion: Provided only moderate inhibition (17–29%) that was highly dependent on the agonist class and failed to block complex stimuli effectively.
• Primary Human Cell Response (MoDCs):
  • SSL3 Fusion: Robustly attenuated inflammatory responses. It significantly reduced IL-8 secretion and transcriptional induction of IL-8, IL-6, and IL-1$\beta$ (7–8 fold reduction compared to WT).
  • SELP Fusion: Failed to broadly suppress inflammation. While it showed a minor reduction in IL-6 transcription, it did not significantly reduce IL-8 or IL-1$\beta$ levels compared to wild-type curli.
  • Viability: All treatments maintained high cell viability, confirming that reduced cytokine production was due to signaling modulation, not cytotoxicity.
• TLR2 Specificity: Pre-treatment with a small-molecule TLR2 inhibitor (TL2-C29) abolished the inflammatory response to wild-type curli, confirming the pathway is TLR2-dependent.

5. Significance and Implications

• Therapeutic Potential: This work establishes a strategy for creating "smart" probiotics that can actively dampen local inflammation at the mucosal surface. An engineered EcN producing TLR2-antagonistic curli could compete with endogenous inflammatory curli in the gut, breaking the self-reinforcing cycle of inflammation seen in IBD and other TLR2-driven pathologies.
• Design Principle: The study highlights that while steric shielding can reduce intrinsic activation, direct receptor antagonism is required for effective blockade in physiologically relevant, ligand-rich environments (like the gut or primary immune cells).
• Modularity: The CsgA scaffold is highly amenable to fusion with diverse protein domains. This suggests a broader platform for engineering bacteria to target other innate immune receptors (e.g., TLR4, NOD2) or to deliver therapeutic payloads specifically to sites of inflammation.
• Future Directions: The authors propose that the fiber-tethered format offers a unique advantage over soluble therapeutics by sustaining local antagonist presentation under the continuous flow of the intestinal lumen, potentially offering superior therapeutic efficacy in vivo.

In summary, the paper successfully transforms a naturally inflammatory bacterial component into a programmable, receptor-specific immune modulator, providing a foundational framework for next-generation engineered living materials.